New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


Anti-cancer treatment designed to lower risk of cancer’s return

New trial evaluating treatment designed to lower the risk of cancer returning Dr. Edward Garon’s Novartis CACZ885T2301 study is now open to enrollment at select TRIO- US sties. This is a randomized phase 3 study evaluating the efficacy an…


Combination Therapy Study Reduces Risk of Death by Half

From Business Wire Combination Therapy Merck announced on August 20, 2018, that the U.S. Food and Drug Administration (FDA) has approved an expanded label for pembrolizumab/KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with peme…


Broad-Based Testing: Will it Improve Survival?

From Cure Magazine: Broad-based genomic sequencing, is useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC). But, it may not improve survival outcomes when compared to routine genomic testing, according t…


FDA Approves Opdivo for Small Cell Lung Cancer

From MedScape The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based c…


Researchers Use Big Data to Predict Immunotherapy Responses

From EurekAlert In the age of Big Data, cancer researchers are discovering new ways to monitor the effectiveness of immunotherapy treatments. Researchers at the Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy develo…


Liquid Biopsy Could Ease the Way to Immunotherapy for Lung Cancer

From NewsWise Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden (TMB) accurately identifies non-small cell lung cancer (NSCLC) patients who could benefi…


Lung cancer mortality rates among women projected to increase

From EurekaAlert Bottom Line: The global age-standardized lung cancer mortality rate among women is projected to increase by 43 percent from 2015 to 2030, according to an analysis of data from 52 countries. The global age-standardized breast…


Could a Simple Blood Test Detect Early-Stage Lung Cancer?

from The ASCO Post If the initial promise of research presented at the 2018 ASCO Annual Meeting bears fruit, we may one day have a simple blood test to screen for early-stage lung cancer and possibly other cancers. Although it is still very …


Blood test improves lung cancer risk assessment for smokers

  From Medical Life Sciences News A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smoke…


Combination Therapy New Standard of Care for Squamous NSCLC

From ASCO Daily News Combining pembrolizumab with conventional chemotherapy in the first-line setting significantly prolongs median overall survival in patients with metastatic squamous non–small cell lung cancer (NSCLC), according to data f…

Read More